Pharming Group N.V.
PHARM.AS · AMS
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -2.95 | 0.50 | -4.69 | -0.75 |
| FCF Yield | -0.39% | -2.01% | 2.04% | 2.97% |
| EV / EBITDA | 52.58 | 105.64 | 29.36 | 13.31 |
| Quality | ||||
| ROIC | -1.39% | -1.10% | 4.48% | 5.47% |
| Gross Margin | 80.81% | 89.72% | 91.46% | 89.37% |
| Cash Conversion Ratio | 0.16 | 1.44 | 1.53 | 1.64 |
| Growth | ||||
| Revenue 3-Year CAGR | 11.74% | 8.92% | -3.44% | 0.09% |
| Free Cash Flow Growth | 86.70% | -189.70% | 3.73% | -72.93% |
| Safety | ||||
| Net Debt / EBITDA | 4.20 | 11.12 | -1.21 | -0.62 |
| Interest Coverage | -0.39 | -0.82 | 3.51 | 4.71 |
| Efficiency | ||||
| Inventory Turnover | 0.80 | 0.44 | 0.41 | 0.74 |
| Cash Conversion Cycle | 436.19 | 675.15 | 788.17 | 431.01 |